IWILFIN Study Results

How IWILFIN was studied

IWILFIN’s effectiveness was assessed in Study 3b, which included pediatric high-risk neuroblastoma patients in remission following completion of upfront therapy. Patients in remission received IWILFIN twice daily for up to 2 years.

Results were compared with an external control database from Study ANBL0032, where patients received the same standard of care regimen up until they received dinutuximab instead of IWILFIN.

Improvement in event free survival

In studies, children taking IWILFIN achieved a 52% reduction in the risk of high-risk neuroblastoma relapse

Improvement in overall survival

Overall, 92% of the children treated with IWILFIN were still alive after 5-years post remission, compared to 79% of the children in the external control group